AppOmni and Cisco Partner to Extend SaaS Security with End-to-End Zero Trust From Endpoint to the Application November 8, 2024
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 September 30, 2024
